Top 10 Insider Buys April 2026: Where CEOs Are Investing Millions Now 📈

🕵️♂️ Inside the Smart Money: MGM, PANW, AHCO & More

Insider Watchlist Snapshot (prices as of Apr-02-2026 close):
NYSE: MGM — $36.68
NASDAQ: PENN — $14.77
NASDAQ: WYNN — $102.03
NYSE: CPNG — $18.95
NASDAQ: ALKT — $16.56
NASDAQ: WVE — $7.28
NYSE: PHR — $8.37
NASDAQ: LYEL — $21.21
NASDAQ: AHCO — $12.03
NASDAQ: WGS — $66.20
NASDAQ: FOX — $52.87
NASDAQ: PANW — $163.21

At FUNanc1al, we love analyst opinions. They are colorful. They are energetic. They are often extremely confident for people who are not writing checks with their own money.

Insiders, on the other hand? They have skin in the game, stock in the game, and occasionally yacht money in the game.

When a CEO, director, or 10% owner reaches into their own velvet-lined pocket and buys millions of dollars’ worth of stock, that is not just “constructive commentary.” That is action. Not a guarantee. Not a cheat code. But definitely a signal worth watching.

So here is the March/April 2026 insider scoreboard: casinos, cyber, biotech, home healthcare, e-commerce, and media all made the cut. In other words, the smart money has been shopping everywhere from blackjack tables to gene-editing labs.

🎲 1. MGM Resorts (MGM): The House Is Buying the House

This is one of the loudest buys of the bunch.

IAC, already a 10% owner, scooped up another 1,000,000 MGM shares around $37.22, a roughly $37.2 million flex. That came on top of a major December purchase and earlier insider buying from the CEO, CFO, and a director. When insiders keep returning to the same table, it usually means they like the odds.

What makes MGM interesting is that the story is not just “Vegas.” It is:

• Las Vegas and regional casino cash flow
• MGM China recovery
• BetMGM digital growth
• giant share repurchases
• a short-interest setup spicy enough to make the bears sweat

MGM’s latest full-year results were a mixed but intriguing cocktail: revenue rose to $17.5 billion, Q4 revenue hit $4.6 billion, BetMGM’s venture distributed $135 million to MGM in Q4, and the company repurchased 37 million shares in 2025. That said, the digital segment still posted an EBITDA loss, so this is not a perfect fairy tale with free room service.

👉 Want the full picture? Dive into MGM Resorts International (MGM)'s financials here.

The FUNanc1al angle: insiders appear to be betting that buybacks, digital scaling, Macau strength, and steady core operations matter more than macro hand-wringing and debt anxiety. Also, institutional ownership north of 100% of float is one of those deliciously weird market-structure stats that says, “This stock is crowded, contested, and capable of drama.”

🔍 For MGM Resorts International (MGM)'s Institutional Ownership breakdown, see here. 

🛒 2. Coupang (CPNG): Neil Mehta Went Full Shopping Cart

Director Neil Mehta did not nibble. He hoovered up more than 7 million shares in a three-day burst around the mid-$18s.

That is not window shopping. That is Black Friday with conviction.

Coupang still fits the classic “Amazon of South Korea” narrative, though investors should always be careful with those lazy analogies because international e-commerce stories come with their own local quirks, margins, and execution risks. Still, the sheer size of the buying says insiders see value where the market still sees “nice company, maybe later.”

🧬 3. Wave Life Sciences (WVE): RNA, RA Capital, and High-Octane Risk

Rajeev Shah of RA Capital has been buying, which instantly raises the seriousness level by several notches.

Wave has all the biotech ingredients:

• exciting platform
• strong institutional sponsorship
• clinical-stage upside
• clinical-stage chaos
• cash-burn and dilution risk lurking behind the curtain like a horror-movie violin score

This is classic asymmetric biotech: if the science works, people start using phrases like “multi-bagger.” If it does not, people start using phrases like “strategic review” — or much worse.

🏥 4. AdaptHealth (AHCO): Daily Accumulation Mode

Richard Cashin Jr. bought again and again and again in March, building what looked less like a trade and more like a campaign.

AHCO has the profile value investors love and momentum investors reluctantly notice:

• home healthcare exposure
• cheap-looking valuation metrics
• high institutional ownership
• solid cash generation
• a stock that has recently woken up from its nap

The company’s Q4 and full-year 2025 results were messy but not disastrous: revenue beat expectations, guidance for 2026 was constructive, and management kept emphasizing operational cleanup, balance-sheet improvement, and strong patient growth. The ugly GAAP number included a large non-cash goodwill impairment, which makes the headline look worse than the underlying operating story.

Translation: insiders may be buying the transition, not the rearview mirror. 

🛡️ 5. Palo Alto Networks (PANW): Nikesh Arora’s $10M Vote

When the CEO of a major cybersecurity powerhouse buys roughly $10 million of stock, people notice.

Cybersecurity is one of those sectors that never really gets to become optional. It is digital oxygen. PANW is not some mystery microcap CEO pounding the table on a dream. It is the boss of a category leader writing a very large check.

That does not make PANW “cheap,” but it does make the signal hard to ignore. 

For our full report on Palo Alto Networks, check this out. 

🧾 6. FOX (FOX): Lachlan Murdoch Bought the Dip

Lachlan Murdoch buying $10.6 million worth of FOX shares is one of those transactions that says, “The person closest to the media machine thinks the market is being a little dramatic.”

Media names rarely get simple narratives. There is always some mix of advertising pressure, politics, streaming headaches, linear-TV decline, and family-dynasty intrigue. Which, to be fair, is half the fun.

For our full report on FOX, check this out.

🧬 7. Lyell Immunopharma (LYEL): High Science, Higher Risk

Arch Venture Fund and another 10% owner were buying.

That tells you two things immediately:

1. serious biotech money still sees upside
2. this is still a clinical-stage company with all the financing and execution risks that implies

The pipeline is real. The science is ambitious. The cash clock is also real. Investors should admire the insider signal while keeping one eye on the treasury.

🧪 8. GeneDx (WGS): Corvex Stayed Interested

Corvex Management bought more WGS, adding over $13 million across two reported purchases.

This fits the theme of institutions and informed capital continuing to back differentiated healthcare/genomics stories. Cathy Wood of Ark Invest has also been accumulating shares. The trick here is not whether GeneDx is interesting. It clearly is. The trick is assessing risks and analyzing business viability and valuation after a stock has experienced a serious pullback.

For our full report on GeneDx, check this out.

💳 9. Alkami (ALKT): General Atlantic Steps In

General Atlantic buying ALKT is a strong “smart private-market brain likes public-market price” signal.

Alkami sits in that fintech/SaaS zone where a good business can still get tossed around like a lawn chair if sentiment turns. Insider or sponsor buying does not remove that volatility, but it can tell you where experienced capital sees attractive long-term setup.

🩺 10. Phreesia (PHR): The Guidance-Dip Shopping Spree

We covered PHR separately here, but it belongs on the list. Big buying into a nasty guidance-driven drop is one of the most classic insider signals in the market.

Sometimes insiders buy because a stock is cheap.
Sometimes because the market missed the point.
Sometimes because both.

PHR looks like one of those “messy but interesting” names where sentiment collapsed faster than the actual business.

🍸 Casino Bonus Round: PENN and WYNN Say Hello

Perhaps not quite in the same current-conviction bucket as MGM for this update, but the overall gambling sector still deserves a wink.

Penn Entertainment (PENN) has seen recurring insider buys by the CEO, CFO, and directors over time, while Wynn Resorts (WYNN) had a notable Fertitta purchase cycle last year at lower levels. The takeaway is not that all casino stocks are instant buys. It is that insiders in gaming seem perfectly willing to gamble on… gambling.

At least they understand the industry.

🎯 The FUNanc1al Bottom Line

The common thread this month is not one sector. It is conviction in strategic winners with identifiable catalysts:

• MGM = buybacks + digital + Macau + squeeze fuel
• CPNG = scale e-commerce with insider size
• WVE/LYEL = high-risk biotech moonshots with real capital backing
• AHCO/PHR = healthcare names insiders think the market is underpricing
• PANW = premium cyber with CEO confidence
• WGS/FOX/ALKT = informed capital backing differentiated stories

If I had to pick one of the cleanest signals here, it is still MGM. The pattern is broad, the size is real, the buybacks are meaningful, and the business has more moving parts than “people lose money in casinos.” But as always: insider buying is a clue, not a covenant.

Quick Take / TL;DR

• Biggest “wow” buy: MGM
• Biggest shopping spree: CPNG
• Highest-risk moonshots: WVE and LYEL
• Best value-ish healthcare signal: AHCO
• Cleanest blue-chip confidence flex: PANW
• Insider buying matters most when it is large, repeated, and clustered

FAQ

Are insider buys always bullish?
No. They are helpful signals, not guarantees. Some insiders buy early, some buy wrong, and some buy into businesses that still deteriorate.

What type of insider buy matters most?
Big open-market purchases, especially repeated ones by CEOs, CFOs, directors, or 10% owners.

Why is MGM the standout here?
Size, repetition, supporting buybacks, short-interest tension, and a diversified operating story.

Should investors blindly copy insiders?
Absolutely not. Follow the signal, then do the homework.

Food for Thought: The Cross-Hub Connection

Insider buying is a lot like ordering in a good restaurant: the menu tells you one story, but the staff ordering the special tells you another. When insiders buy heavily, they are often revealing where they think value, momentum, or underappreciated catalysts still live.

About the Author

Frédéric Marsanne is the founder of FUNanc1al — part market analyst, part storyteller, part accidental comedian. A longtime investor, entrepreneur, and venture-builder across tech, biotech, and fintech, he now blends sharp insights with a twist of humor to help readers laugh, learn, live better lives, and invest a little wiser. When not decoding insider buys or poking fun at earnings calls, he’s building Cl1Q, writing fiction, painting, or discovering new passions to FUNalize. 

🧾⚠️📢 Fun(anc1al) but Serious Disclaimer: 🧾⚠️📢

This is not financial advice. Insider buys are useful signals, not guaranteed jackpots. Some insiders are brilliant. Some are early. Some are wrong. And some companies with heavy insider buying still manage to light shareholder value on fire. Do your own research, mind dilution and debt, and never confuse “interesting” with “safe.”

This article is for educational and entertainment purposes only and does not constitute financial advice. Stocks go down. Sometimes a lot. Sometimes for good reasons. Sometimes for no reason at all. Investing in them involves significant risk, including loss of capital. Always do your own research, know your risk tolerance, and consult a licensed financial professional if needed. 

Past performance is not indicative of future results. Resist FOMO and never invest money you can’t afford to lose or mistake a charismatic CEO for a guarantee. 

We laugh, we analyze, we meme.
We’re FUNanc1al — not advisors. 😄📉📈

Invest at your own risk! 🎢📉
Love at any pace. Laugh at every turn. 😄

Be Happy. 😄😄

🧭 Looking for a Different Angle?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny